# Living+ Peptides > Education-only reference on peptides: FDA status, compounding rules and published research, with primary sources. Run by Living+ (https://livingplusrx.com/). Education only: this site sells nothing, makes no treatment claims for unapproved peptides, and cites primary sources (FDA, Federal Register, DailyMed, PubMed, ClinicalTrials.gov). Each peptide page has a status box with a "Last verified" date and links to the primary records checked. Doses appear only as doses used in published studies, with citations. Dosing is set by a licensed provider. Every peptide, regulation, comparison, guide and news page has a clean Markdown copy: drop the trailing slash and add .md (for example https://livingpluspeptides.com/peptides/bpc-157.md). It carries the same text, FAQs and numbered sources as the page. ## Key pages - [FDA Peptide Status Tracker](https://livingpluspeptides.com/regulation/tracker/): FDA and compounding status of 26 peptides, with a last verified date on every row. - [Peptide regulation](https://livingpluspeptides.com/regulation/): The laws, rules and FDA actions that decide which peptides can be prescribed and compounded. - [Peptides A to Z](https://livingpluspeptides.com/peptides/): Index of every peptide profile. - [Status Tracker as CSV](https://livingpluspeptides.com/regulation/tracker.csv): The same tracker data as a CSV file, one row per peptide, with source links. - [Compare](https://livingpluspeptides.com/compare/): Peptide pairs side by side, with FDA, pharmacy and sport status. - [Guides](https://livingpluspeptides.com/guides/): Plain-language guides: what a peptide is, reading a study, safety, prescribing. - [News](https://livingpluspeptides.com/news/): Dated FDA, DEA and WADA actions that affect peptides. RSS: /news/rss.xml ## Peptides - [AOD-9604](https://livingpluspeptides.com/peptides/aod-9604/): AOD-9604 facts: FDA compounding status, the 2024 advisory committee vote, WADA ban, obesity trials, doses used in studies and side effects. - [BPC-157](https://livingpluspeptides.com/peptides/bpc-157/): BPC-157 facts: FDA and compounding status in 2026, WADA status, what rat and small human studies looked at, and known safety gaps. - [Bremelanotide (PT-141)](https://livingpluspeptides.com/peptides/bremelanotide-pt-141/): Bremelanotide (PT-141): FDA approval as Vyleesi, the exact label indication, label safety data, studies, compounding rules and WADA status. - [Cagrilintide](https://livingpluspeptides.com/peptides/cagrilintide/): Cagrilintide FDA status (not approved), why FDA says it cannot be compounded, CagriSema and REDEFINE trial results, and reported side effects. - [CJC-1295](https://livingpluspeptides.com/peptides/cjc-1295/): CJC-1295 (with and without DAC) FDA status, the 2024 compounding committee vote, WADA status, and the small human studies done so far. - [Epitalon](https://livingpluspeptides.com/peptides/epitalon/): Epitalon (epithalon) facts: FDA compounding status, the July 2026 advisory committee review, WADA status, studies and doses used in research. - [GHK-Cu](https://livingpluspeptides.com/peptides/ghk-cu/): GHK-Cu copper peptide: FDA 503A status after the 2026 changes, cosmetic versus drug rules, topical human studies, safety notes and WADA status. - [GHRP-2 and GHRP-6](https://livingpluspeptides.com/peptides/ghrp-2-ghrp-6/): GHRP-2 (pralmorelin) and GHRP-6 FDA status, 503A and 503B compounding categories, WADA status, and the human studies from the 1990s. - [Ipamorelin](https://livingpluspeptides.com/peptides/ipamorelin/): Ipamorelin FDA status, the 2024 compounding committee vote, its 503B category 2 listing, WADA status, and the human studies to date. - [Kisspeptin](https://livingpluspeptides.com/peptides/kisspeptin/): Kisspeptin: FDA 503A Category 2 status for kisspeptin-10, the 2024 advisory vote, WADA status, and human studies in IVF and low sexual desire. - [KPV](https://livingpluspeptides.com/peptides/kpv/): KPV (lysine-proline-valine) facts: FDA and compounding status in 2026, WADA status, and what animal and lab studies tested. No human trials exist. - [Liraglutide](https://livingpluspeptides.com/peptides/liraglutide/): Liraglutide FDA status, Victoza, Saxenda and generic labels, its ongoing FDA shortage listing, compounding rules, key trials and label safety. - [LL-37](https://livingpluspeptides.com/peptides/ll-37/): LL-37 (human cathelicidin) facts: FDA compounding status and safety concerns in 2026, WADA status, and what ulcer, melanoma and lab studies tested. - [Melanotan II](https://livingpluspeptides.com/peptides/melanotan-ii/): Melanotan II safety and legal page: FDA actions, import alert, compounding status, published case reports of harm, and WADA status. - [MK-677 (Ibutamoren)](https://livingpluspeptides.com/peptides/mk-677/): MK-677 (ibutamoren) facts: FDA compounding category 2 status, WADA status, human trials, doses used in studies and reported side effects. - [MOTS-c](https://livingpluspeptides.com/peptides/mots-c/): MOTS-c facts: FDA compounding status, the July 2026 advisory committee review, WADA ban, animal research and doses used in studies. - [Oxytocin](https://livingpluspeptides.com/peptides/oxytocin/): Oxytocin: FDA-approved obstetric uses of Pitocin and generic injections, label warnings, intranasal research, compounding rules and WADA status. - [Retatrutide](https://livingpluspeptides.com/peptides/retatrutide/): Retatrutide FDA status (not approved), why FDA says it cannot be compounded, phase 2 and phase 3 TRIUMPH trial results, and reported side effects. - [Selank](https://livingpluspeptides.com/peptides/selank/): Selank facts: FDA compounding status, WADA status, anxiety studies, animal research and doses used in published studies. - [Semaglutide](https://livingpluspeptides.com/peptides/semaglutide/): Semaglutide FDA status, Ozempic, Wegovy and Rybelsus labels, the 2025 end of the shortage, compounding rules, key trials and label safety. - [Semax](https://livingpluspeptides.com/peptides/semax/): Semax facts: FDA compounding status, the July 2026 advisory committee review, status in Russia and WADA, studies and doses used in research. - [Sermorelin](https://livingpluspeptides.com/peptides/sermorelin/): Sermorelin (Geref) FDA history, why it left the market, its compounding and WADA status, and the human studies on growth hormone release. - [TB-500 and Thymosin Beta-4](https://livingpluspeptides.com/peptides/tb-500-thymosin-beta-4/): TB-500 and thymosin beta-4: how they differ, FDA and compounding status in 2026, WADA status, and what animal and human studies tested. - [Tesamorelin](https://livingpluspeptides.com/peptides/tesamorelin/): Tesamorelin (Egrifta SV, Egrifta WR) FDA approval, label dosing and warnings, compounding and WADA status, and the key HIV belly fat and liver trials. - [Thymosin Alpha-1](https://livingpluspeptides.com/peptides/thymosin-alpha-1/): Thymosin alpha-1 (thymalfasin): US FDA and compounding status, the 2024 FDA advisory vote, status outside the US, and what human trials tested. - [Tirzepatide](https://livingpluspeptides.com/peptides/tirzepatide/): Tirzepatide FDA status, Mounjaro and Zepbound labels, the end of the shortage, compounding rules, SURPASS and SURMOUNT trials, and label safety. ## Regulation - [503A vs 503B pharmacies: who can compound what](https://livingpluspeptides.com/regulation/503a-vs-503b-pharmacies/): How federal law splits drug compounding between 503A pharmacies and 503B outsourcing facilities: prescriptions, CGMP, inspections and bulk ingredients. - [Category 1 vs Category 2 bulk substances explained](https://livingpluspeptides.com/regulation/category-1-vs-category-2-bulk-substances/): What FDA's interim Category 1, 2 and 3 lists for nominated compounding ingredients mean, which peptides are on them, and what withdrawn means. - [Compounded vs FDA-approved drugs](https://livingpluspeptides.com/regulation/compounded-vs-fda-approved-drugs/): What FDA approval means, what drug compounding is, how the two differ, and the risks FDA has named for compounded drugs. - [Peptide rules by state: how pharmacy boards differ](https://livingpluspeptides.com/regulation/peptide-rules-by-state/): How state pharmacy boards differ on licensing, sterile compounding, office-use compounding and telehealth prescribing, with examples from state laws. - [Peptides in sport: the WADA list and testing](https://livingpluspeptides.com/regulation/peptides-in-sport-wada/): Which peptides the WADA Prohibited List bans under S0, S2 and S4, what changes in the 2027 List, and how anti-doping testing is done. - [Research use only peptides: why they are not for human use](https://livingpluspeptides.com/regulation/research-use-only-peptides/): What a research use only label means under federal drug law, how FDA judges intended use, and what FDA warning letters say about these peptides. ## Comparisons - [503A Pharmacy vs 503B Outsourcing Facility](https://livingpluspeptides.com/compare/503a-vs-503b-pharmacy/): 503A pharmacies and 503B outsourcing facilities side by side: who oversees them, what they may compound, prescriptions vs office use, and the key rules. - [BPC-157 vs TB-500: FDA status, research and differences](https://livingpluspeptides.com/compare/bpc-157-vs-tb-500/): BPC-157 vs TB-500: neither is FDA approved. Where each came from, what animal and human studies tested, July 2026 FDA review, and WADA status. - [CJC-1295 vs Ipamorelin: FDA Status and Research](https://livingpluspeptides.com/compare/cjc-1295-vs-ipamorelin/): CJC-1295 and ipamorelin compared: how each acts on growth hormone, FDA and compounding status, human studies, half-life and FDA safety concerns. - [Compounded vs FDA-Approved Semaglutide](https://livingpluspeptides.com/compare/compounded-vs-fda-approved-semaglutide/): How compounded semaglutide differs from FDA-approved semaglutide: FDA review, evidence, adverse event reports, salt forms and the rules since 2025. - [Semaglutide vs Tirzepatide: FDA status and research](https://livingpluspeptides.com/compare/semaglutide-vs-tirzepatide/): Semaglutide vs tirzepatide: FDA approvals, receptor targets, half-life, compounding status, and the SURPASS-2 and SURMOUNT-5 head-to-head trials. - [Sermorelin vs Tesamorelin: FDA status and research](https://livingpluspeptides.com/compare/sermorelin-vs-tesamorelin/): Sermorelin vs tesamorelin: two GHRH analogs. One was approved and discontinued, one is FDA approved today. Studies, half-life, compounding and WADA. - [Tirzepatide vs Retatrutide: FDA status and research](https://livingpluspeptides.com/compare/tirzepatide-vs-retatrutide/): Tirzepatide vs retatrutide: one is FDA approved, one is experimental. Receptor targets, trial results, half-life, compounding and WADA status. ## Guides - [How peptides are prescribed in the US](https://livingpluspeptides.com/guides/how-peptides-are-prescribed/): How peptide drugs reach patients in the US: FDA-approved prescriptions, off-label use, 503A and 503B compounding, and DEA telemedicine rules. - [How to read a peptide study](https://livingpluspeptides.com/guides/how-to-read-a-peptide-study/): Learn to judge peptide research: lab vs animal vs human studies, randomized trials, sample size, trial phases and ClinicalTrials.gov records. - [Peptide safety basics](https://livingpluspeptides.com/guides/peptide-safety-basics/): FDA's stated risks of unapproved and compounded peptides, injection and immune reaction risks, and how to report a problem to FDA MedWatch. - [What is a peptide?](https://livingpluspeptides.com/guides/what-is-a-peptide/): A plain guide to peptides: amino acids, how peptides differ from proteins, natural peptide hormones and peptide drugs, with NIH and FDA sources. ## News - [HHS interim policy covers 6 peptides for compounding](https://livingpluspeptides.com/news/hhs-interim-peptide-compounding-policy/): 2026-10-28. On Oct 28, 2026 HHS said it will not act against 503A compounding of BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500 under conditions. Not FDA approval. - [WADA 2027 List names peptides as S0 examples](https://livingpluspeptides.com/news/wada-2027-prohibited-list-peptides/): 2026-09-21. WADA published its 2027 Prohibited List in September 2026, in force January 1, 2027. S0 now names peptides as examples. GLP-1 status is unchanged. - [FDA advisers review seven peptides for compounding](https://livingpluspeptides.com/news/pcac-july-2026-peptides/): 2026-07-24. FDA's compounding advisers met July 23-24, 2026 on BPC-157, KPV, TB-500, MOTS-c, emideltide, Semax and Epitalon. FDA staff proposed against all seven. - [FDA proposes keeping GLP-1s off the 503B bulks list](https://livingpluspeptides.com/news/glp1-503b-bulks-list-proposal/): 2026-05-01. A May 1, 2026 FDA notice proposes leaving semaglutide, tirzepatide and liraglutide off the 503B bulks list. Comments closed July 30, 2026. - [Most peptides leave FDA's Category 2 list](https://livingpluspeptides.com/news/fda-category-2-peptides-withdrawn-2026/): 2026-04-22. FDA's Category 2 list now names only kisspeptin-10 and ibutamoren from this site. BPC-157, TB-500 and others left after nominators withdrew. - [FDA warns 30 telehealth firms over compounded GLP-1 ads](https://livingpluspeptides.com/news/fda-warns-telehealth-compounded-glp1/): 2026-03-03. On March 3, 2026, FDA announced 30 warning letters to telehealth firms over claims that compounded GLP-1s match approved drugs or hide who makes them. - [DEA telemedicine flexibilities run through 2026](https://livingpluspeptides.com/news/dea-telemedicine-extension-2026/): 2025-12-31. DEA and HHS extended telemedicine prescribing of controlled medications through December 31, 2026. None of the peptides on this site is DEA controlled. ## About this site - [Editorial policy](https://livingpluspeptides.com/editorial-policy/): How pages are researched, written, reviewed and updated. - [Sources policy](https://livingpluspeptides.com/sources-policy/): Which sources are cited and which are never cited. - [Corrections log](https://livingpluspeptides.com/corrections/): Every material correction, with the date. - [Disclaimer](https://livingpluspeptides.com/disclaimer/): Educational information, not medical advice. Contact: info@livingplusrx.com Reporters: editor@livingpluspeptides.com (https://livingpluspeptides.com/for-reporters/)